Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.648 USD | -0.46% | -1.93% | -3.01% |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 26.1 | 27.74 | 50.31 | 19.88 | 22.22 | 22 | - | - |
Enterprise Value (EV) 1 | 26.1 | 27.74 | 50.31 | 19.88 | 22.22 | 22 | 22 | 22 |
P/E ratio | -1.34 x | -2.7 x | -1.68 x | -0.24 x | -1.06 x | -0.86 x | -0.99 x | -1.58 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - | - | - |
EV / EBITDA | - | -1.45 x | -1.74 x | -0.35 x | -0.87 x | -0.76 x | -0.65 x | -0.56 x |
EV / FCF | - | - | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 693 | 1,293 | 3,985 | 7,860 | 8,139 | 8,307 | - | - |
Reference price 2 | 37.65 | 21.45 | 12.62 | 2.530 | 2.730 | 2.648 | 2.648 | 2.648 |
Announcement Date | 3/5/20 | 2/25/21 | 3/22/22 | 3/30/23 | 2/29/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - |
EBITDA 1 | - | -19.08 | -29 | -57.53 | -25.52 | -28.8 | -34 | -39 |
EBIT 1 | -20.09 | -19.14 | -29.05 | -57.6 | -25.71 | -28.22 | -31.87 | -33.5 |
Operating Margin | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -19.36 | -19.01 | -28.97 | -56.7 | -23.17 | -25.9 | -30.03 | -38.7 |
Net income 1 | -19.36 | -8.15 | -27.47 | -54.22 | -20.84 | -25.9 | -30.03 | -28.3 |
Net margin | - | - | - | - | - | - | - | - |
EPS 2 | -28.20 | -7.950 | -7.500 | -10.47 | -2.580 | -3.080 | -2.680 | -1.680 |
Free Cash Flow | - | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 3/5/20 | 2/25/21 | 3/22/22 | 3/30/23 | 2/29/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA 1 | -6.954 | -6.841 | -6.613 | -6.713 | -7.319 | -6.494 | -6.796 | -6.828 | -5.917 | -5.978 | -6.4 | -6.8 | -7.2 | -8.4 |
EBIT 1 | -6.968 | -6.849 | -6.62 | -6.72 | -7.327 | -6.541 | - | -6.875 | -5.964 | -6.025 | -6.911 | -6.911 | -6.911 | -6.911 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -6.927 | -6.794 | -6.705 | -6.626 | -37.38 | -5.991 | -6.187 | -6.357 | -5.261 | -5.365 | -6.062 | -6.262 | -6.462 | -7.112 |
Net income 1 | -6.927 | -6.794 | -4.226 | -6.626 | -37.38 | -5.991 | -6.187 | -4.027 | -5.261 | -5.365 | -6.062 | -6.262 | -6.462 | -7.112 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -1.800 | -1.650 | -1.050 | -1.650 | -7.880 | -0.7600 | -0.7700 | -0.5000 | -0.6500 | -0.6600 | -0.7250 | -0.7500 | -0.7650 | -0.8400 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/4/21 | 3/22/22 | 5/5/22 | 8/4/22 | 11/10/22 | 3/30/23 | 5/9/23 | 8/14/23 | 11/2/23 | 2/29/24 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex | - | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - | - |
Announcement Date | 3/5/20 | 2/25/21 | 3/22/22 | 3/30/23 | 2/29/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.01% | 22M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- LSTA Stock
- Financials Lisata Therapeutics, Inc.